Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
American Depositary Shares^F6,F2,F7	Jan 18, 2018	P	335,050	$101.00	A	708,025	I	See Footnotes
American Depositary Shares^F6,F3,F7	Jan 18, 2018	P	1,645,148	$101.00	A	5,121,404	I	See Footnotes
Ordinary shares^F1,F2,F7	holding	—	—		—	6,533,135	I	See Footnotes
Ordinary shares^F1,F3,F7	holding	—	—		—	73,162,022	I	See Footnotes
American Depositary Shares^F4	holding	—	—		—	7,102	D
American Depositary Shares^F5	holding	—	—		—	7,102	D

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1Ordinary shares of BeiGene, Ltd. (the "Issuer") are convertible into American Depository Shares ("ADS") on a 13:1 basis.
F2As a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by 667, L.P. ("667"), a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
F3As a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's Ordinary Shares or ADS, as applicable, reported in column 5 of Table I directly held by Baker Brothers Life Sciences, L.P. ("Life Sciences", together with 667, the "Funds"), a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
F4Reflects 7,102 ADS of the Issuer held directly by Julian C. Baker received from the in-kind pro rata distribution without consideration reported above.
F5Reflects 7,102 ADS of the Issuer held directly by Felix J. Baker received from the in-kind pro rata distribution without consideration reported above.
F6On January 18, 2018, 667 and Life Sciences purchased 335,050 and 1,645,148 American Depositary Shares of the Issuer, respectively, each representing 13 Ordinary Shares (the "ADS") for $101.00 per ADS, pursuant to an underwritten public offering.
F7Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Remarks

Michael Goller and Ranjeev Krishana, employees of Baker Bros. Advisors LP, are directors of BeiGene, Ltd. (the "Issuer"). By virtue of their representation on the Board of Directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.